R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to compare the efficacy and safety of R±CEOP90 containing
high-dose epirubicin and R±CEOP75 containing standard epirubicin in newly diagnosed young
patients with medium/high-risk diffuse large B-cell lymphoma. Half of the participants
receive R±CEOP regimen containing 90mg/m2 epirubicin, while the other half of participants
receive R±CEOP regimen containing 75mg/m2 epirubicin. Via exploring whether high-dose
epirubicin shall achieve better efficacy and less toxicity, we hope to optimize current
treatment choice for young patients with medium/high-risk diffuse large B-cell lymphoma.